KRAS and mucinous adenocarcinoma: The study reported by Picco et al.14 did not find a correlation between response to MLN4924 monotherapy and clinically relevant CRC molecular drivers (KRAS mutation, BRAF mutation, and microsatellite instability); however, transcriptional profiling of a cohort of mCRC tumors suggested that high-grade mucinous carcinomas could be a responsive subgroup14.